BIO Cautions Against Using Comparative Effectiveness Data To Cut Coverage

Comparative-effectiveness studies sponsored by the Agency for Healthcare Research & Quality (AHRQ) could serve as the basis for denying Medicare coverage to beneficial drugs if research results are "applied inappropriately," according to the Biotechnology Industry Organization